Literature DB >> 18347077

Mesothelin expression in the leptomeninges and meningiomas.

Mahlon D Johnson1, Fran Vito, Mary J O'Connell.   

Abstract

The identity and functions of surface proteins on human leptomeningeal and meningioma cells are incompletely characterized. Some structural and functional similarities between the leptomeninges and pleura suggest that proteins important to pleural function and tumorigenesis might also be relevant to leptomeningeal disease. Mesothelin is a recently described, 40-kDa membrane protein expressed in pleura. Its functions in this tissue are under investigation. Sections of 20 normal adult brains with leptomeninges and 49 World Health Organization (WHO) grade I, 21 grade II, and 2 grade III meningiomas were analyzed using an extensively characterized monoclonal antibody to mesothelin and streptavidin-biotin complex immunohistochemistry. Five meningiomas were also evaluated by Western blot. Mesothelin immunoreactivity was detected in the arachnoid in 6 of 20 cases and in 23 of 49 WHO grade I meningiomas. It was also detected in 7 of 21 WHO II tumors and 1 of the 2 anaplastic meningiomas. By Western blot, all five meningiomas exhibited mesothelin precursor protein, including one where notable immunoreactivity was not identified in a formalin-fixed tissue section. These findings suggest that mesothelin is expressed in at least some arachnoid and meningioma cells. Future studies may clarify its role in the development of meningiomas, meningeal seeding of gliomas, and metastases to the leptomeninges.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347077      PMCID: PMC2386771          DOI: 10.1369/jhc.2008.950477

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  24 in total

1.  New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.

Authors:  Masanori Onda; Mark Willingham; Satoshi Nagata; Tapan K Bera; Richard Beers; Mitchell Ho; Raffit Hassan; Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates.

Authors:  Nirag Jhala; Darshana Jhala; Selwyn M Vickers; Isam Eltoum; Surinder K Batra; Upender Manne; Mohamad Eloubeidi; Jennifer J Jones; William E Grizzle
Journal:  Am J Clin Pathol       Date:  2006-10       Impact factor: 2.493

3.  Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.

Authors:  N Scholler; N Fu; Y Yang; Z Ye; G E Goodman; K E Hellström; I Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.

Authors:  Masanori Onda; Satoshi Nagata; Mitchell Ho; Tapan K Bera; Raffit Hassan; Richard H Alexander; Ira Pastan
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

5.  Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.

Authors:  Raffit Hassan; Alan T Remaley; Maureen L Sampson; Jingli Zhang; Derrick D Cox; James Pingpank; Richard Alexander; Mark Willingham; Ira Pastan; Masanori Onda
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

6.  Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.

Authors:  Arnaud Scherpereel; Bogdan Grigoriu; Massimo Conti; Thomas Gey; Marc Grégoire; Marie-Christine Copin; Patrick Devos; Bachar Chahine; Henri Porte; Philippe Lassalle
Journal:  Am J Respir Crit Care Med       Date:  2006-02-02       Impact factor: 21.405

Review 7.  Microscopic morphology and histology of the human meninges.

Authors:  R O Weller
Journal:  Morphologie       Date:  2005-03

8.  Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants.

Authors:  R Wellenreuther; A Waha; Y Vogel; D Lenartz; J Schramm; O D Wiestler; A von Deimling
Journal:  Lab Invest       Date:  1997-12       Impact factor: 5.662

9.  Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas.

Authors:  K Chang; I Pastan; M C Willingham
Journal:  Int J Cancer       Date:  1992-06-19       Impact factor: 7.396

10.  Molecular cloning and expression of megakaryocyte potentiating factor cDNA.

Authors:  T Kojima; M Oh-eda; K Hattori; Y Taniguchi; M Tamura; N Ochi; N Yamaguchi
Journal:  J Biol Chem       Date:  1995-09-15       Impact factor: 5.157

View more
  5 in total

Review 1.  Amatuximab and novel agents targeting mesothelin for solid tumors.

Authors:  Paolo Baldo; Sara Cecco
Journal:  Onco Targets Ther       Date:  2017-11-08       Impact factor: 4.147

2.  Do mesothelin/MUC16 interactions facilitate adenocarcinoma metastases to intracranial meningiomas?

Authors:  Mahlon D Johnson
Journal:  Surg Neurol Int       Date:  2016-12-21

3.  Human Malignant Rhabdoid Tumor Antigens as Biomarkers and Potential Therapeutic Targets.

Authors:  Timothy Hua; Ziwei Zeng; Junji Chen; Yu Xue; Yan Li; Qingxiang Sang
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

4.  Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.

Authors:  Seunggu J Han; Gerald Reis; Gary Kohanbash; Shruti Shrivastav; Stephen T Magill; Annette M Molinaro; Michael W McDermott; Philip V Theodosopoulos; Manish K Aghi; Mitchel S Berger; Nicholas A Butowski; Igor Barani; Joanna J Phillips; Arie Perry; Hideho Okada
Journal:  J Neurooncol       Date:  2016-09-13       Impact factor: 4.506

5.  Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma.

Authors:  Ernest Dodoo; Markus Maeurer; Zhenjiang Liu; Martin Rao; Thomas Poiret; Silvia Nava; Qingda Meng; Anna von Landenberg; Jiri Bartek; Shanshan Xie; Georges Sinclair; Inti Peredo
Journal:  Oncotarget       Date:  2017-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.